EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY 4.0

Current Understanding of Immune Thrombocytopenia: A Review of Pathogenesis and Treatment Options

Alina Mititelu, Minodora-Cezarina Onisâi iD, Adrian Roșca, Ana Maria Vlădăreanu

International Journal of Molecular Sciences · 10.02.2024 · 25 (4) · 2163

DOI: 10.3390/ijms25042163 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift International Journal of Molecular Sciences, online erschienen am 10.02.2024. Verfasst von Alina Mititelu und 3 weiteren Autor:innen. Beteiligte Einrichtung: Department of Hematology, Carol Davila University of Medicine and Pharmacy, Emergency University Hospital of Bucharest, 050098 Bucharest, Romania. Hauptthemen laut MEDLINE: Purpura, Thrombocytopenic, Idiopathic, Thrombocytopenia. Die Arbeit wurde bisher 101-mal zitiert (Crossref) und nennt 105 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

The management of immune thrombocytopenia (ITP) and the prediction of patient response to therapy still represent a significant and constant challenge in hematology. ITP is a heterogeneous disease with an unpredictable evolution. Although the pathogenesis of ITP is currently better known and its etiology has been extensively studied, up to 75% of adult patients with ITP may develop chronicity, which represents a significant burden on patients’ quality of life. A major risk of ITP is bleeding, but knowledge on the exact relationship between the degree of thrombocytopenia and bleeding symptoms, especially at a lower platelet count, is lacking. The actual management of ITP is based on immune suppression (corticosteroids and intravenous immunoglobulins), or the use of thrombopoietin receptor agonists (TPO-RAs), rituximab, or spleen tyrosine kinase (Syk) inhibitors. A better understanding of the underlying pathology has facilitated the development of a number of new targeted therapies (Bruton’s tyrosine kinase inhibitors, neonatal Fc receptors, strategies targeting B and plasma cells, strategies targeting T cells, complement inhibitors, and newer TPO-RAs for improving megakaryopoiesis), which seem to be highly effective and well tolerated and result in a significant improvement in patients’ quality of life. The disadvantage is that there is a lack of knowledge of the predictive factors of response to treatments, which would help in the development of an optimized treatment algorithm for selected patients.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Purpura, Thrombocytopenic, IdiopathicThrombocytopeniaAdultInfant, NewbornHumansQuality of LifePlatelet CountImmunoglobulins, IntravenousThrombopoietinRecombinant Fusion Proteins

Stichwörter der Autor:innen

ITPSYK inhibitorsTPO-RApathogenesisplatelet desialylationrituximabsplenectomy

Substanzen

Immunoglobulins, IntravenousThrombopoietinRecombinant Fusion Proteins

Autor:innen und Institutionen

  • Department of Hematology, Carol Davila University of Medicine and Pharmacy, Emergency University Hospital of Bucharest, 050098 Bucharest, Romania.
  • Department of Physiology, Carol Davila University of Medicine and Pharmacy, 050471 Bucharest, Romania.

ORCID-Profile: Minodora-Cezarina Onisâi

Zitieren

APA

Mititelu, A., Onisâi, M. C., Roșca, A., & Vlădăreanu, A. M. (2024). Current Understanding of Immune Thrombocytopenia: A Review of Pathogenesis and Treatment Options. International Journal of Molecular Sciences, 25(4), 2163. https://doi.org/10.3390/ijms25042163

Vancouver

Mititelu A, Onisâi MC, Roșca A, Vlădăreanu AM. Current Understanding of Immune Thrombocytopenia: A Review of Pathogenesis and Treatment Options. International Journal of Molecular Sciences. 2024;25(4):2163. doi:10.3390/ijms25042163

BibTeX
@article{Mititelu2024,
  author = {Mititelu, Alina and Onisâi, Minodora-Cezarina and Roșca, Adrian and Vlădăreanu, Ana Maria},
  title = {Current Understanding of Immune Thrombocytopenia: A Review of Pathogenesis and Treatment Options},
  journal = {International Journal of Molecular Sciences},
  year = {2024},
  volume = {25},
  number = {4},
  pages = {2163},
  doi = {10.3390/ijms25042163}
}
Kostenlos starten →